Select studies addressing prognosis and the effect of HCT in patients with R/R PTCL using the time point of relapse as baseline
| . | GLA/LYSA AATT10,11 . | Heidelberg15 . | MDACC41 . | Milan INT23 . | Int. T-cell project6 . |
|---|---|---|---|---|---|
| Study type | RCT, post-hoc retrospective | Single-center retrospective | Registry retrospective | Single-center retrospective | Registry retrospective |
| Eligibility | NOS, AITL, ALCL ALK, EATL, HSTL, R/R on trial | Any R/R PTCL, consecutive | R/R AITL/NOS, consecutive | Any R/R PTCL, alloHCT eligible, consecutive | Any R/R PTCL |
| N | 50 | 91 | 240 | 73 | 633 |
| Relapsed | 20 (40%) | 44 (48%) | 162 (67%) | 38 (52%) | 197 (31%) |
| Primary refractory | 30 (60%) | 47 (52%) | 78 (33%) | 35 (48%) | 436 (69%) |
| Period | 2011-2021 | 2001-2014 | 1999-2014 | 2001-2017 | 2006-2016 |
| HCT for R/R disease | 26 (52%) | 38 (42%) | 67 (28%) | 45 (62%) | 99 (16%) |
| AlloHCT | 25 (50%) | 31 (34%) | 31 (13%) | 45 (62%) | 23 (4%) |
| AutoHCT | 1 (2%) | 7 (8%) | 36 (15%) | - | 76 (12%) |
| Strategy | Physician's discretion | ITT alloHCT | Physician's discretion | ITT alloHCT | Physician's discretion |
| Age (years; median [range]) | 50 (24-58)a | 51/63 (21-72)b | 60 (23-83) | 55 (18-68) | 59 (18-89) |
| PS >1 (ECOG) or <70% (Karnofsky) | 20%a | NA | 19% | NA | 23% |
| Prior autoHCT (at study entry) | 40% | 48%/−b | 18% | 23% | 8% |
| Overall survival from R/R (ITT) | 33% (crude) | 20% (5 y) | 20-24% (5 y) | 34% (4 y) | 23% (3 y) |
| OS from R/R with alloHCT | |||||
| 3 y | 68%c | 60% | 52%c | 57%c | |
| 5 y | 65% | 52% | 52% | 51% (4 y) | |
| OS from R/R with autoHCT | |||||
| 3 y | 14% | 55%c | 48%d | ||
| 5 y | 0% | 32% | 42%c,d | ||
| OS from R/R without HCT | |||||
| 3 y | 11%c | 3% | 19%c | NA | 18% |
| 5 y | 11%c | 3% | 10% | 19% (4 y) | NA |
| Untransplanted patients among those surviving ≥3 ye | 2/18 (11%) | 2/18 (11%) | NA | 2/22 (9%) | - |
| Follow-up from R/R (mo) | NA | 70 (17-148) | NA | 40 (9-192) | 38 (1-96) |
| . | GLA/LYSA AATT10,11 . | Heidelberg15 . | MDACC41 . | Milan INT23 . | Int. T-cell project6 . |
|---|---|---|---|---|---|
| Study type | RCT, post-hoc retrospective | Single-center retrospective | Registry retrospective | Single-center retrospective | Registry retrospective |
| Eligibility | NOS, AITL, ALCL ALK, EATL, HSTL, R/R on trial | Any R/R PTCL, consecutive | R/R AITL/NOS, consecutive | Any R/R PTCL, alloHCT eligible, consecutive | Any R/R PTCL |
| N | 50 | 91 | 240 | 73 | 633 |
| Relapsed | 20 (40%) | 44 (48%) | 162 (67%) | 38 (52%) | 197 (31%) |
| Primary refractory | 30 (60%) | 47 (52%) | 78 (33%) | 35 (48%) | 436 (69%) |
| Period | 2011-2021 | 2001-2014 | 1999-2014 | 2001-2017 | 2006-2016 |
| HCT for R/R disease | 26 (52%) | 38 (42%) | 67 (28%) | 45 (62%) | 99 (16%) |
| AlloHCT | 25 (50%) | 31 (34%) | 31 (13%) | 45 (62%) | 23 (4%) |
| AutoHCT | 1 (2%) | 7 (8%) | 36 (15%) | - | 76 (12%) |
| Strategy | Physician's discretion | ITT alloHCT | Physician's discretion | ITT alloHCT | Physician's discretion |
| Age (years; median [range]) | 50 (24-58)a | 51/63 (21-72)b | 60 (23-83) | 55 (18-68) | 59 (18-89) |
| PS >1 (ECOG) or <70% (Karnofsky) | 20%a | NA | 19% | NA | 23% |
| Prior autoHCT (at study entry) | 40% | 48%/−b | 18% | 23% | 8% |
| Overall survival from R/R (ITT) | 33% (crude) | 20% (5 y) | 20-24% (5 y) | 34% (4 y) | 23% (3 y) |
| OS from R/R with alloHCT | |||||
| 3 y | 68%c | 60% | 52%c | 57%c | |
| 5 y | 65% | 52% | 52% | 51% (4 y) | |
| OS from R/R with autoHCT | |||||
| 3 y | 14% | 55%c | 48%d | ||
| 5 y | 0% | 32% | 42%c,d | ||
| OS from R/R without HCT | |||||
| 3 y | 11%c | 3% | 19%c | NA | 18% |
| 5 y | 11%c | 3% | 10% | 19% (4 y) | NA |
| Untransplanted patients among those surviving ≥3 ye | 2/18 (11%) | 2/18 (11%) | NA | 2/22 (9%) | - |
| Follow-up from R/R (mo) | NA | 70 (17-148) | NA | 40 (9-192) | 38 (1-96) |
Patients with salvage alloHCT only.
Patients with salvage alloHCT/autoHCT only.
Estimated from published survival plots.
Pooled autoHCT and alloHCT.
In studies with at least 33% HCT rate.
ALK−, ALK-negative; EATL, enteropathy-associated T-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; NA, not available.